16 research outputs found
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men
Leren zien
De wereld telt nog te veel vermijdbare
blindheid. Glaucoom bijvoorbeeld is door de Wereldgezondheidsorganisatie
nog niet eens genoemd in het VISION 2020-programma,
omdat er nog zoveel andere dingen te doen zijn. Wereldwijd moeten wij
oogartsen ons schamen. Glaucoom is nog een belangrijke oorzaak van
blindheid, ook al valt er veel te winnen bij de trabeculectomie.
Dat komt door te late opsporing en doordat te weinig oogartsen de
glaucoomoperatie willen uitvoeren.Wij zien een wereld waarin nog te veel mensen onnodig blind zijn.
Wij zien een gezondheidszorg waarin managers patiënten zien als
kaskoeien
Leren zien
De wereld telt nog te veel vermijdbare
blindheid. Glaucoom bijvoorbeeld is door de Wereldgezondheidsorganisatie
nog niet eens genoemd in het VISION 2020-programma,
omdat er nog zoveel andere dingen te doen zijn. Wereldwijd moeten wij
oogartsen ons schamen. Glaucoom is nog een belangrijke oorzaak van
blindheid, ook al valt er veel te winnen bij de trabeculectomie.
Dat komt door te late opsporing en doordat te weinig oogartsen de
glaucoomoperatie willen uitvoeren.Wij zien een wereld waarin nog te veel mensen onnodig blind zijn.
Wij zien een gezondheidszorg waarin managers patiënten zien als
kaskoeien
Rectus extraocular muscle paths and decompression surgery for Graves orbitopaty : Mechanism of motility disturbances
Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis.
Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis.
PURPOSE: To identify the possible risk factors for the development of cataract requiring surgery in children with juvenile idiopathic arthritis (JIA)-associated uveitis. DESIGN: Retrospective cohort study. METHODS: Data of 53 children with JIA-associated uveitis, of whom 27 had undergone cataract extraction (CE), were obtained. The main outcome measure, the interval between the onset of uveitis and the first CE (U-CE interval), was examined in relation to clinical and ophthalmologic characteristics and treatment strategies before CE. RESULTS: A shorter U-CE interval was found for children with posterior synechia vs those without posterior synechia (hazard ratio [HR], 3.57; 95% confidence interval [CI], 1.33 to 10.00). No significant difference was found for children in whom the uveitis was the first manifestation of JIA vs those in whom arthritis was the first manifestation of JIA (HR, 1.59; 95% CI, 0.63 to 4.00) and children treated with periocular corticosteroid injections vs those not treated with periocular corticosteroid injections (HR, 3.23; 95% CI, 0.95 to 11.11). Children treated with methotrexate (MTX) had a longer U-CE interval than children not treated with MTX (HR, 0.29; 95% CI, 0.10 to 0.87). CONCLUSIONS: The risk factor for development of early cataract requiring surgery in children with JIA-associated uveitis is the presence of posterior synechia at the time of diagnosis of uveitis. However, early treatment with MTX is associated with a mean delay in the development of cataract requiring surgery of 3.5 years